In response to the urgent need for increased vaccine manufacturing capacity amidst the COVID-19 pandemic, we are proud to announce our latest project: the development of a new industrial production process for ARNm synthesis enzymes. Supported by the ERDF of the European Union and the Junta de Castilla y León, this initiative aims to address the critical shortage of vaccine supplies by enhancing the efficiency and scalability of production.
By leveraging cutting-edge technology and strategic partnerships, we are committed to driving innovation and contributing to a more competitive and resilient healthcare ecosystem. Join us as we embark on this crucial mission to empower global vaccination efforts and safeguard public health.
DEVELOPMENT OF A NEW INDUSTRIAL PRODUCTION PROCESS OF ARNm SYNTHESIS ENZYMES AS A SOLUTION TO THE LACK OF STOCK IN THE MANUFACTURE OF VACCINES AGAINST COVID-19.
File No: 14/21/VA/0006
Deadline for completion: From 15/02/2020 to 31/03/2023
The project is being carried out in Boecillo (Valladolid), with an approximate duration of 38 months (2020-2023) and a budget of 973,336.53 €.
This project has been supported by the ERDF of the European Union and the Junta de Castilla y León, through the ICE, with the aim of achieving a more competitive business fabric.
DESARROLLO DE UN NUEVO PROCESO PRODUCTIVO INDUSTRIAL DE ENZIMAS DE SÍNTESIS DE ARNm COMO SOLUCIÓN A LA FALTA DE STOCK EN LA FABRICACIÓN DE VACUNAS CONTRA EL COVID-19
Expediente nº: 14/21/VA/0006
Plazo de realización: Desde el 15/02/2020 al 31/03/2023
El proyecto se desarrolla en Boecillo (Valladolid), con una duración aproximada de 38 meses (2020-2023) y cuenta con un presupuesto de 973.336,53 €.
Este proyecto ha sido apoyado por el FEDER de la Unión Europea y la Junta de Castilla y León, a través del ICE, con el objetivo de conseguir un tejido empresarial más competitivo.
About 53Biologics:
53Biologics is a CDMO with specialized in biologics production, from pDNA, mRNA and proteins. It is a leading biopharma company providing services from preclinical and clinical development to GMP manufacturing, supporting our clients in getting their biological products to market as quickly as possible.
For more information contact Patricia De La Madrid, Marketing & Business Development Manager at 53Biologics through this email: pdelamadrid@53biologics.com